Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Duvelisib (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms DYNAMO+R
- Sponsors Infinity Pharmaceuticals; Verastem Oncology
- 18 Dec 2021 This trial has been completed in Italy and Hungary (End date:2016-10-05) and discontinued in Belgium, according to European Clinical Trials Database.
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
- 13 Apr 2017 This trial has been completed in Denmark (End date:2017-03-03) and discontinued in Belgium, according to European Clinical Trials Database.